Recent Posts

anonymous said:

Fuck that. Roommates are an HR nightmare. So glad I left Nofartus.

Click to expand...

anonymous said:

more coming for ma with realignment. oncology business most impacted and was told its within us. leadership was notified last friday and will be implemented before fall national meeting according to source from VP ties

Click to expand...

anonymous said:

Popularity contest vs meritocracy. And it keeps getting worse.

Click to expand...

anonymous said:

Oncology launches often fail because management repeatedly hires the same people across companies. They create a safe bubble with no accountability or responsibility. Kite is a prime example: Gilead spent $13 billion on the acquisition, yet Kite faced no pressure to meet sales targets or achieve specific goals—unsurprisingly, it failed. This reflects poor leadership. When billions are spent acquiring oncology assets that hinge on successful launches, leadership should closely monitor performance. Leadership squandered the profits generated by hardworking sales teams, overpaying at the expense of shareholders. Meanwhile, Galapagos is still laughing, with billions in the bank

Click to expand...